nificantly greater IOP variation (p = 0.034) during follow-up, and that these patients tended to require IOP-lowering treatment more frequently (p = 0.090). Conclusion: Multiple anti-VEGF injections lead to an increase in IOP, although this variation is not sufficient to cause development of OHT in the majority of patients.
effect of multiple anti-VEGF injections remains controversial [4] [5] [6] . In our study, we aimed to evaluate the effect of intravitreal anti-VEGF agents on IOP variation and on the development of sustained ocular hypertension (OHT) in patients with neovascular AMD, and to correlate it with factors related to the patient and treatment characteristics.
Materials and Methods
We performed a retrospective review of a cohort of patients with neovascular AMD treated between August 2007 and September 2014 at a tertiary care center (Hospital de São João, Porto, Portugal). The study protocol was approved by the Ethics Committee of Health of the Hospital de São João and followed the tenets of the Declaration of Helsinki.
Patients with AMD who received intravitreal anti-VEGF treatment in one eye during the study period and no current or previous intravitreal anti-VEGF treatment in the fellow eye were eligible for this study. The following exclusion criteria were considered: other causes of choroidal neovascularization, a history of glaucoma or OHT before the first anti-VEGF injection, current or previous intraocular inflammation, a history of photodynamic therapy, local or systemic steroid treatment, and a previous retina surgery or any ocular surgery (except for glaucoma) during follow-up in either eye. Patients' records were reviewed to collect all relevant data, including information related to the patient [age at baseline and at the final evaluation, phakic status, and pseudoexfoliation (PEX) syndrome] and treatment regimen (number of injections, interval between injections, and type of anti-VEGF agent). Eyes treated with intravitreal anti-VEGF injections were included in the study group and fellow eyes were used as controls. Anti-VEGF therapy included bevacizumab (1.25 mg/0.05 ml), ranibizumab (0.5 mg/0.05 ml), and/or aflibercept (2 mg/0.05 ml). Intravitreal injections were performed in the operating room under topical anesthesia using a sharp 30-gauge needle. After the injection, patients received ofloxacin eye drops 5 times daily for 5 days. No steroids were given. None of the eyes received IOP-lowering medications or anterior-chamber paracentesis before or after intravitreal injection. It should be noted that the pro re nata dosing regimen was used in all patients.
IOP was measured with Goldmann applanation tonometry at least twice in each eye at each visit. All visits occurred in the afternoon, between 2: 00 and 7: 00 p.m. The baseline IOP was measured at the visit before the first injection and the final IOP was determined 3-4 weeks after the last injection. If a patient needed IOPlowering therapy, because of the development of OHT and/or changes in optic disc morphology, the last IOP measurement without treatment was considered the final IOP. OHT was defined as a sustained IOP >21 mm Hg at 3 consecutive visits.
Statistical analysis was performed using SPSS statistical software (version 20.0 for Windows; SPSS Inc., Chicago, Ill., USA). The data are presented as means ± SD. IOP values are expressed in millimeters of mercury. Data was tested for normality and homogeneity of variances. Parametric values, i.e. differences in IOP measurements between study and control eyes, were statistically evaluated using the Student t test. Pearson's correlation coefficient (r) was used to assess the relationship between IOP variation and demographic or treatment characteristics of the patients. Multiple linear regressions were conducted to identify the most influential variables in IOP variation. Regressions were performed using the stepwise method. Subjects' age and sex, baseline IOP, injection number and interval, and follow-up were included as covariables in the regressions. p < 0.05 was considered statistically significant.
Results
Seventy-two patients fulfilled the selection criteria and were included in the analysis. As mentioned previously, treated eyes (n = 72) were included in the study group and noninjected fellow eyes (n = 72) were used as controls. The mean age of the study population at baseline was 76.58 ± 6.83 years (range 57-90), and 58.3% were women. The mean follow-up period was 30.9 ± 21.6 months (range 1-75), and 38.9% of the patients were treated with bevacizumab only, 19.4% received ranibizumab only, and 41.7% were given multiple anti-VEGF agents (bevacizumab, ranibizumab, and/or aflibercept). The mean number of injections was 15.6 ± 12.4 (range 1-44). PEX syndrome was present in 5.4% of the injected eyes and 4.1% of the controls (p = 0.698), and 29.7% of the eyes in both groups were pseudophakic (p = 1.00).
The baseline and final IOP values in the total sample, the study group, and the control group are presented in table 1 . The mean final IOP was higher than the mean baseline IOP in all groups, but the difference only reached statistical significance in the total sample (p = 0.045). Mean baseline IOP values were similar in the study and control groups (14.93 ± 2.71 vs. 14.91 ± 2.60, respectively; p = 0.974) while the mean final IOP was slightly higher in During follow-up, OHT developed in 3 of the injected eyes (4.2%) and 1 of the controls (1.4%). The characteristics of these patients are shown in table 2 . In all patients who developed sustained OHT, IOP was controlled with drops, except in 1 patient who also needed glaucoma surgery. This patient only developed OHT in the injected eye although he had PEX syndrome bilaterally. Table 3 describes the main features of the patients included in the study group, according to the number of injections received during follow-up ( ≤ 20 vs. >20). Baseline patient characteristics (gender, age, phakic status, and PEX syndrome) were similar in both subgroups. On the other hand, patients with a greater number of injections had significantly shorter intervals between injections (p = 0.001), were more frequently treated with a combination of anti-VEGF agents (p < 0.001), and had a longer follow-up (p < 0.001). While no significant IOP variation was noted during follow-up in patients receiving ≤ 20 injections, there was a significant increase in IOP with time in more frequently treated patients (mean IOP variation +2.20 ± 4.49, p = 0.041). In addition to this, a comparison of both subgroups demonstrated that patients receiving >20 injections suffered significantly greater IOP variation (p = 0.034) during follow-up, and that these patients tended to require IOP-lowering treatment more frequently (p = 0.090).
IOP variation correlated negatively with baseline IOP and positively with the number of injections received. Given the observed correlations, a regression equation was defined to predict IOP variation based on these variables as follows: IOP variation = 5.061 -0.362 × baseline IOP + 0.081 × injection number. This regression model, which is statistically significant (p = 0.006), explains 18% of the IOP variation. Patient age, sex, follow-up, and injection interval did not influence the model and were removed from the regressions. 
Discussion
Our results show that repeated intravitreal injections of anti-VEGF agents are associated with an increase in IOP, even though this is not sufficient to lead to the development of OHT in the majority of patients. The IOP tended to increase during follow-up in both the study group and the control group, which is consistent with the fact that the mean IOP increases with age [4] . In the study group, however, this increase was larger and almost reached statistical significance.
When we analyzed the results obtained in the study group according to the number of injections received, we verified that the IOP variation was significantly larger in patients who received a higher number of injections [7] . As the IOP increases with age and patients who receive a higher number of injections have on average a longer follow-up, the greater IOP variation in this group could be explained by the longer follow-up. However, after controlling for the potentially confounding effect of a longer follow-up period through multiple linear regression, the number of injections remained a significant predictor of IOP variation. This suggests that multiple intravitreal anti-VEGF injections may in fact lead to a sustained increase in IOP and even to the development of sustained OHT in a subset of patients. Similar findings were reported by Hoang et al. [7, 8] .
Sustained OHT developed in 4.2% (n = 3) of the injected eyes, which is consistent with previous reports (3.45-11%) [9] [10] [11] [12] [13] [14] [15] . In contrast, sustained OHT was observed in only 1.4% (n = 1) of the fellow noninjected eyes. Despite this apparent difference, the number of eyes that developed this outcome is too small to draw any definitive conclusions. All patients who developed OHT had a controlled IOP with medical therapy, except one who also required glaucoma surgery. Previous reports [15] [16] [17] have shown that a sustained IOP after repeated intravitreal injections might need surgical procedures in addiction to drops.
In the study group, the proportion of patients who required IOP-lowering treatment was higher in those who received >20 injections (19.2 vs. 4.3%). However, these results must be interpreted with caution because, due to the retrospective nature of this study, IOP-lowering treatment was initiated at the discretion of the managing physician when the patient developed sustained OHT or suspicious changes in optic disc morphology were noted. Thus, the criteria for initiating treatment were not rigorously defined and standardized, and in most patients optic disc OCT or computerized perimetry to confirm optic disc damage was not performed.
Several authors have reported the development of a sustained increased IOP in a subset of patients receiving anti-VEGF therapy for neovascular AMD [7] [8] [9] [10] [11] [12] 14] . The pathophysiological mechanisms responsible for this potential adverse effect remain elusive but may include: traumatic trabecular meshwork injury caused by the repeated expansion of the eye's volume after injections [5, 18] , and blockade of the aqueous humor outflow via the trabecular meshwork secondary to anti-VEGF biological effects or protein aggregates and contaminant particles [5, 14] . However, none of the studies published to date conclusively establishes a causal relationship between anti-VEGF therapy and a sustained rise in IOP, as these studies are case series or retrospective reviews with a relatively small sample size and many of them lack a proper control group [4, 15] .
In our study, only patients who received intravitreal anti-VEGF treatment in one eye during the study period and no current or previous intravitreal anti-VEGF treatment in the fellow eye were eligible. Thus, we were able to use noninjected fellow eyes as controls, ensuring an adequately matched control group. On the other hand, it should be noted that noninjected eyes may not be true controls as they may also suffer the effects of the anti-VEGF agent injected in the fellow eye and subsequently absorbed into the systemic circulation [19] . This may have led to underestimation of the differences between the study and control groups and of the long-term effect of anti-VEGF intravitreal therapy on IOP.
The reviewed patients were followed up on average for a long period of time (i.e. 30.9 ± 21.6 months, range 1-75). On the other hand, like other studies published to date, ours is retrospective in nature and thus susceptible to selection bias.
Although eyes receiving >20 anti-VEGF injections suffer a significantly larger IOP variation than eyes treated with fewer injections, this variation may not be great enough to lead to the development of sustained OHT.
In the future, prospective studies with an appropriate control group and a large sample size are needed to further clarify the long-term effect of anti-VEGF therapy on IOP in patients with neovascular AMD. Until then, physicians involved in AMD management should be aware that a sustained IOP increase is a possible adverse effect of anti-VEGF agents. If this proves to be true, the development of sustained OHT seems to be a relatively infrequent effect, but it may still have a serious impact by increasing ocular morbidity in patients already afflicted by AMD.
